Market capitalization | GBP4.48b |
Enterprise Value | GBP5.51b |
P/E (TTM) P/E ratio | 36.94 |
EV/FCF (TTM) EV/FCF | 29.83 |
EV/Sales (TTM) EV/Sales | 3.15 |
P/S ratio (TTM) P/S ratio | 2.56 |
P/B ratio (TTM) P/B ratio | 3.43 |
Dividend yield | 2.23% |
Last dividend (FY23) | GBP0.05 |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
17 Analysts have issued a Convatec Group forecast:
17 Analysts have issued a Convatec Group forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,748 1,748 |
1%
1%
|
|
Gross Profit | 954 954 |
2%
2%
|
|
EBITDA | 420 420 |
11%
11%
|
EBIT (Operating Income) EBIT | 246 246 |
21%
21%
|
Net Profit | 122 122 |
111%
111%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions. The company was incorporated in 1978 and is headquartered in Reading, the United Kingdom.
Head office | United Kingdom |
CEO | Karim Bitar |
Employees | 10,136 |
Founded | 1978 |
Website | www.convatec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.